Details : NMS-293 has strong potential in combination with a wide variety of DNA-damaging agents, including systemic or targeted chemotherapy (Antibody-Drug Conjugates) or with DNA damage response inhibitors, in numerous tumor types.
Product Name : NMS-293
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 21, 2022
Lead Product(s) : MEN1611,Fulvestrant,Trastuzumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results of the phase 1b dose escalation study of MEN1611, a PI3K Inhibitor, combined with trastuzumab ± fulvestrant for HER2+/PIK3CA mutant advanced or metastatic breast cancer will be presented at the 2020 Virtual Annual Congress of the European Societ...
Product Name : MEN1611
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2020
Lead Product(s) : MEN1611,Fulvestrant,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable